jlharley at my-dejanews.com wrote in message
<7e016d$6qc$1 at nnrp1.dejanews.com>...
>What is the recommended safe daily dosage (mg) of Acetaminophen? Any info
is
>greatly appreciated. Thanks. (jl68harley at aol.com)
There may be no "safe" dose of acetaminophen if one believes the studies
showing acetaminophen cause cancer in mice and rats. Scientists generally
believe that acetaminophen is a threshold carcinogen (i.e., acetaminophen
does not cause cancer a low doses, but promotes cancer formation only at
very high doses that are also toxic to the liver. With this in mind, safe
therapeutic doses range from 2 mg/day to 5 mg/day. With alcohol consumption
the "safe" dose of acetaminophen may be much smaller.
I suggest that you review the following sites for additional information and
discussion of these issues:
The Parkinsn List Drug Database
acetaminophen, Tylenol™
http://www.ionet.net/~jcott/homepage/drugdb/001.html
NTP CHEMICAL REPOSITORY (RADIAN CORPORATION, AUGUST 29, 1991)
4-HYDROXYACETANILIDE (also known as acetaminophen).
http://ntp-db.niehs.nih.gov/NTP_Reports/NTP_Chem_H&S/NTP_Chem1/Radian103-90-
2.txt
Tylenol Overdoses Linked To Acute Failure of Liver
By DENISE GRADY
The New York Times, October 16, 1997
http://www.cqs.com/tylenol.htm
Tylenol Maker Tells Parents of Health Risks
New York Times, October 19, 1997
http://www.cqs.com/tylalert.htm
Carcinogenic Dose-Response Assessment for Acetaminophen:
A Comparison with Other Threshold Carcinogens
James S. Smith, Jr.
http://www.oak-creek.net/abst-2.html
-------------------------------------------------------------------------
James S. Smith, Jr., Ph.D.
Toxicologist & President
OAK CREEK, Inc.
Toxicology & Risk Assessment Consulting
RR 3 Box 246B
Route 22
Gorham, Maine 04038-9428
Voice : (207) 929-6375
Fax : (207) 929-6374
E-mail: jssmith at oak-creek.net
WWW: http://www.oak-creek.net/
begin 666 James S. Smith, Jr., Ph.D..vcf
M0D5'24XZ5D-!4D0-"E9%4E-)3TXZ,BXQ#0I..E-M:71H+"!*<BXL(%!H+D0N
M.TIA;65S.U,N#0I&3CI*86UE<R!3+B!3;6ET:"P at 2G(N+"!0:"Y$+ at T*3U)'
M.D]!2R!#4D5%2RP at 26YC+B @5&]X:6-O;&]G>2 F(%)I<VL at 07-S97-S;65N
M="!#;VYS=6QT:6YG#0I4251,13I0<F5S:61E;G0@)B!4;WAI8V]L;V=I<W0-
M"DY/5$4Z26YD97!E;F1E;G0 at 0V]N<W5L=&%N="!I;B!T:&4 at 16YV:7)O;FUE
M;G1A;"!38VEE;F-E<RX-"E1%3#M73U)+.U9/24-%.B at R,#<I(#DR.2TV,S<U
M#0I414P[2$]-13M63TE#13HH,C W*2 Y,CDM-C,W-0T*5$5,.U=/4DL[1D%8
M.B at R,#<I(#DR.2TV,S<T#0I414P[2$]-13M&05 at Z*#(P-RD at .3(Y+38S-S0-
M"D%$4CM73U)+.T5.0T]$24Y'/5%53U1%1"U04DE.5$%"3$4Z.SM24C, at 0F]X
M(#(T-D(],$0],$%2;W5T92 R,CM';W)H86T[36%I;F4[,#0P,S at M.30R.#M5
M4T$-"DQ!0D5,.U=/4DL[14Y#3T1)3D<]455/5$5$+5!224Y404),13I24C,@
M0F]X(#(T-D(],$0],$%2;W5T92 R,CTP1#TP04=O<FAA;2P at 36%I;F4@,#0P
M,S at M.30R.#TP1#TP055300T*0412.TA/344[14Y#3T1)3D<]455/5$5$+5!2
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$4D0-"@``
`
end
